Bad and Good News in Pathophysiology, Prevention, and Management of Sepsis

  • R. P. Dellinger


To date, models that describe the interactions of inflammatory mediators during severe sepsis are dominated by a single mediator (e.g. IL-1 or TNF) and often fail to account for the redundancy and interdependence of inflammatory responses. The net response elicited by a cytokine on a target cell is not an isolated event, but depends on the state of cell-associated cytokine receptors (which may be up or down-regulated) and the presence of other pro-inflammatory and counter-regulatory molecules. Ascribing qualifiers of benefit or harm to any inflammatory mediator (e.g. IL-1 or TNR) depends on the clinical context and the net effects of change over time during an infection.


Septic Shock Severe Sepsis Acute Lung Injury Good News Noninvasive Positive Pressure Ventilation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cross AS, Opal SM, Palardy JE et al (1993) The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 167: 112–118PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC (1996) Sir Issac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125–1128PubMedCrossRefGoogle Scholar
  3. 3.
    Bone RC (1996) Why sepsis trials fail. JAMA 276: 565–566PubMedCrossRefGoogle Scholar
  4. 4.
    Mira JP, Cariou A, Grall F et al (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282: 501–568CrossRefGoogle Scholar
  5. 5.
    Westendorp RGJ, Hottenga J-J, Slagboom PE (1999) Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354: 561–563PubMedCrossRefGoogle Scholar
  6. 6.
    Westendorp RGJ, Langermans JAM, Huizinga TWJ et al (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349: 170–173PubMedCrossRefGoogle Scholar
  7. 7.
    Perez J, Dellinger RP (2000) Sepsis definitions. In: Eichacker PQ, Pugin J (eds) Evolving concepts in sepsis and septic shock. Kluwer Academic, Norwell (in press)Google Scholar
  8. 8.
    Reinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, doseranging study. Crit Care Med 24: 733–742PubMedCrossRefGoogle Scholar
  9. 9.
    Hack CE, DeGroot ER, Felt-Bersma RJF et al (1989) In plasma levels of interleukin-6 in sepsis. Blood 7: 1704–1710Google Scholar
  10. 10.
    Dinarello CA, Gelfland JA, Wolff SM (1993) Anticytokine strategies in the treatment of systemic inflammatory response syndrome. JAMA 269: 1829–1835PubMedCrossRefGoogle Scholar
  11. 11.
    Dellinger RP (1997) Tumor necrosis factor in septic shock and multiple system trauma. Crit Care Med 25: 1771–1773PubMedCrossRefGoogle Scholar
  12. 12.
    Kollef MH (1999) The prevention of ventilator-associated pneumonia. N Engl J Med 340: 627–634PubMedCrossRefGoogle Scholar
  13. 13.
    Darouiche RO, Raad I, Heard SO et al (1999) A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 340: 1–8PubMedCrossRefGoogle Scholar
  14. 14.
    Romaschin AD, Harris DM, Ribeiro MB et al (1998) A rapid assay of endotoxin in whole blood using autologous neutrophil-dependent chemiluminescence. J Immunol Methods 212: 169–185PubMedCrossRefGoogle Scholar
  15. 15.
    Abraham E, Glauser MP, Butler T et al (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. JAMA 277: 1531–1538PubMedCrossRefGoogle Scholar
  16. 16.
    Kushner I (1990) C-reactive protein and the acute phase response. Hosp Pract 25: 13–28Google Scholar
  17. 17.
    Chwals WJ, Fernandez M, Jamie A et al (1994) Detection of postoperative sepsis in infants with the use of metabolic stress monitoring. Arch Surg 129: 437–442PubMedCrossRefGoogle Scholar
  18. 18.
    Shaw AC (1991) Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infection. J Clin Pathol 44: 596–599PubMedCrossRefGoogle Scholar
  19. 19.
    Yentis SM, Soni N, Sheldon J (1998) C-reactive protein as a indicator of resolution of sepsis in the intensive care unit. Inten Care Med 21: 602–605CrossRefGoogle Scholar
  20. 20.
    Provoa P, Almeida E, Moreira P (1998) C-reactive protein as an indicator of sepsis. Inten Care Med 24: 1052–1056CrossRefGoogle Scholar
  21. 21.
    Ugarte H, Silva E, Mercan D (1999) Procalcitonin as a marker of infection in the intensive care unit. Crit Care Med 27: 498–504PubMedCrossRefGoogle Scholar
  22. 22.
    Linden PK (1999) Management of hospital-acquired infection: Focus on Gram-positive resistance. Medical Education Network Presentations in Focus: Report’s and Expert Commentary. [From data presented at a symposium at the Society of Critical Care Medicine 28th Educational and Scientific Symposium]Google Scholar
  23. 23.
    Dellinger RP, Opal SM, Rotrosen D et al and the Future of Sepsis Research Planning Committee and Panel Members (1997) From the bench to the bedside. The future of sepsis research. Executive Summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest 111: 744–753CrossRefGoogle Scholar
  24. 24.
    The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308CrossRefGoogle Scholar
  25. 25.
    Meduri GU, Headley AS, Golden E et al (1998) Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 280: 159–165PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2001

Authors and Affiliations

  • R. P. Dellinger

There are no affiliations available

Personalised recommendations